Graves眼病4种治疗方案汇总,快收藏!

2019-01-20 张崇 医学界内分泌频道

眼部损害是Graves病最常见的甲状腺外表现,又称Graves眼病(GO),是一种器官特异性自身免疫病。女性发病率约为0.016%,男性为0.003%。虽然发生率不是很高,但病情严重者可危及视力,需要积极处理。由于其发病机制目前尚不十分清楚,临床诊治较为困难。本文对目前的常用治疗方案进行总结。

眼部损害是Graves病最常见的甲状腺外表现,又称Graves眼病(GO),是一种器官特异性自身免疫病。女性发病率约为0.016%,男性为0.003%。虽然发生率不是很高,但病情严重者可危及视力,需要积极处理。由于其发病机制目前尚不十分清楚,临床诊治较为困难。本文对目前的常用治疗方案进行总结。

01
突眼严重程度及活动度评估

中国甲状腺疾病诊疗指南-甲状腺功能亢进症,对甲亢突眼度的严重程度和活动度评价采用了美国甲状腺协会1997年的分类标准以及Graves眼病欧洲研究组2006年的评估标准。鉴于美国和欧洲的相关指南已更新过多次,本文采用欧洲2016年指南的标准,具体如下(表1)。

表1



突眼活动度采用临床活动积分(CAS)评估,共计有7项:自发性球后疼痛、凝视或眼球活动时疼痛、眼睑充血、结膜充血、眼睑水肿、眼部炎性反应、结膜水肿,每项1分,累计≥3分为活动性,<3分为非活动性。

02
轻度突眼的治疗方案

大多数轻度 GO 患者仅需随访观察。此外,应积极控制甲状腺功能异常,避免吸烟,同时采取局部治疗措施(人工眼泪及润滑软膏)。对病程较短的轻度 GO 患者给予为期 6个月的硒制剂治疗可能有效。

抗甲状腺药物及甲状腺切除术均不影响 GO 病程。然而,放射碘治疗可导致 GO 发生或进展的风险轻度升高。当高危 GO 患者在放射碘治疗时,应预防性服用泼尼松。

一般认为,泼尼松起始剂量为0. 3 ~ 0. 5 mg·kg-1 ·d-1 ,治疗周期为3个月;低危患者可给予0. 2 mg·kg-1 ·d-1 ,持续6周。对于不存在其他危险因素(尤其是吸烟)的非活动性 GO 患者,在接受放射碘治疗时,无需糖皮质激素预防

03
中重度突眼的一线治疗方案

大剂量静脉糖皮质激素仍是目前治疗中重度活动性 GO 的首选,其疗效及耐受性明显优于口服给药。对于多数患者,可采用静脉滴注甲泼尼龙,起始剂量500 mg,每周 1 次,持续 6 周;随后减至 250 mg 每周 1 次,持续 6 周,一个疗程共计 12 周,累积剂量 4. 5 g。

针对病情严重的GO 患者,甲泼尼龙推荐以 750 mg起始,每周 1 次,持续 6 周,继以 500 mg 每周 1 次,持续 6 周(累积剂量7. 5 g)。

出于安全性考虑,建议:
①单次剂量<750 mg,累计剂量<8 g,同时避免连续 2 d 治疗;
②治疗前应行肝酶、肝炎病毒标志物、空腹血糖及肝脏超声检查;
③治疗期间应每月监测肝酶、血糖及血压;
④推荐常规使用质子泵抑制剂预防消化道溃疡;
⑤治疗过程中应适当补钙,尤其是对存在多个骨质疏松危险因素的患者;
⑥新近发生病毒性肝炎、肝功能明显异常、严重血管并发症、未控制的高血压、精神异常、糖尿病血糖控制不佳,为激素冲击治疗的禁忌证。

治疗后2周之内显效与否是预测长期疗效的重要因素。一般而言,静脉糖皮质激素冲击治疗不应持续超过12 周。

04
中重度突眼的二线治疗方案

如果患者拒绝接受糖皮质激素重新治疗或因其不良反应而无法耐受时,且GO 仍处于活动期,可以考虑以下 4 种方案:

1、眼眶照射治疗:能有效改善复视及眼球运动,并可协同增强口服糖皮质激素的疗效。单侧眼眶照射治疗累计剂量20 Gy,分10 d 进行,持续2周的方案最为常用。眼眶照射可引起轻微的眶周症状或 GO 一过性加重,可使用小剂量口服糖皮质激素进行预防和控制。

2、环孢素A与糖皮质激素联用:口服泼尼松(60~100mg/d起始,逐渐减量,3 个月后停药)联合环孢素 A(5~7.5 mg·kg-1 ·d-1,维持 12 个月)治疗中重度活动性GO效果明显优于单用糖皮质激素且复发率大幅降低。

环孢素 A 最常见的不良反应为剂量依赖的肝肾毒性、牙龈增生,偶有肌酐轻度升高。

3、利妥昔单抗:对于活动性 GO 患者,利妥昔单曾抗被认为是静脉糖皮质激素 治疗无效时的首选,但其疗效如何目前仍有争议,不推荐用于即将发生视神经病变的患者。输液反应是利妥昔单抗最为常见的短期不良反应,偶可见一过性眶周水肿,更有甚者可导致严重感染及多发灶脑白质病。治疗前使用抗组胺药物及 100 mg 氢化可的松可减少不良反应发生。

4、其它药物治疗:曲安奈德(40mg/ml)眶周注射可改善近期初发活动性 GO 的复视及眼外肌大小,其不良反应主要为眼内压一过性升高。其他药物包括硫唑嘌呤、生长抑素类似物等,但疗效轻微或未经证实。免疫球蛋白静脉冲击与大剂量口服糖皮质激素疗效相仿,然而,高昂的费用及病毒扩散副作用限制了其广泛运用。

05
极重度突眼的治疗方案

甲亢相关的视神经病变(DON)与角膜破裂是威胁视力的两大因素,需紧急治疗。严重角膜暴露应采取药物或手术以避免角膜破裂。近期进展的脉络膜褶皱(眼外肌增粗导致眼球凹陷)及眼球半脱位,应尽快行眼眶减压术。

一般而言,超大剂量静脉糖皮质激素(甲泼尼龙500 ~ 1000mg 连续治疗3d或在第1周内隔日冲击)应作为DON 治疗的一线选择。

如果治疗后DON缓解或在2周后改善,应继续每周一次甲泼尼龙治疗,其疗程同中重度活动性GO。若2周内疗效不明显或疗效欠佳,或视觉功能迅速恶化,应立即行眼眶减压手术。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2021-06-07 ms4000001736763111

    总结的好好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-05-08 xinmeili
  3. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-03-08 jyzxjiangqin

    眼部损害的甲状腺疾病的治疗。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-02-20 jyzxjiangqin

    自身免疫性疾病的治疗。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-02-13 jyzxjiangqin

    甲状腺眼病的治疗方案。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-02-01 jyzxjiangqin

    眼病损害的治疗方式。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-01-23 jyzxjiangqin

    甲状腺疾病治疗。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=971457, encodeId=8c3d9e1457fb, content=总结的好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=495f5445599, createdName=ms4000001736763111, createdTime=Mon Jun 07 09:31:36 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039598, encodeId=f9c02039598ca, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed May 08 06:42:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905084, encodeId=71c31905084d3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 22 16:42:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362267, encodeId=979936226e86, content=眼部损害的甲状腺疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 08 17:55:44 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361075, encodeId=52653610e561, content=自身免疫性疾病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 20 06:54:53 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360509, encodeId=79a236050947, content=甲状腺眼病的治疗方案。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 13 06:54:08 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359757, encodeId=ada5359e57ae, content=眼病损害的治疗方式。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Feb 01 19:25:56 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358976, encodeId=47eb3589e6fd, content=甲状腺疾病治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 23 07:01:33 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515315, encodeId=c79c151531554, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540518, encodeId=f33b1540518d4, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Tue Jan 22 01:42:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-01-22 pps20023

相关资讯

Thyroid:自噬与Graves眼病的发生发展相关

关于Graves眼病(GO)的发病机制目前尚未完全清楚。比较可能的机制是眼肌周围的成纤维细胞(perimysial fibroblast)、眼球后脂肪组织的脂肪细胞和成纤维细胞的细胞膜上有促甲状腺激素受体(TSH-R)。T细胞作用于上述有TSH-R的细胞,分泌细胞因子,刺激这些细胞增生,分泌糖胺聚糖(glycosaminoglycan)和表达主要组织相容性复合物(MHC class Ⅱ)抗原(HL

Invest Ophthalmol Vis Sci:磷脂酰肌醇3-激酶特异性抑制剂Idelalisib对Graves眼病的脂肪生成具有抑制作用

韩国首尔延世大学医学院视觉研究所的Ko J和Kim JY近日在Invest Ophthalmol Vis Sci杂志上发表了一篇文章。新的研究表明,磷脂酰肌醇3-激酶(PI3K)-AKT途径参与Graves眼眶病变(GO),并在其发病机制中具有重要作用。这研究中,作者在体外GO眼眶成纤维细胞中使用选择性PI3K抑制剂idelalisib进行处理,研究其对脂肪合成的治疗效果。